Literature DB >> 19589490

Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study.

Mats Remberger1, Berit Sundberg.   

Abstract

In a prospective study we determined rabbit-IgG (r-IgG) levels in serum samples before (day 0) and after (days 1 and 7) unrelated donor hematopoietic stem cell transplantation (HSCT). Most patients suffered from a hematologic malignancy. All patients received rabbit antithymocyte globulin (ATG) as part of the conditioning for 2-4 days (2 mg/kg/day). We found a good correlation (r = 0.34, r = 0.42 and r = 0.46) between the dose of ATG and serum r-IgG levels at all 3 time points. The cumulative incidence of acute graft-versus-host disease (aGVHD) grades II-IV in patients given the 4, 6, and 8 mg/kg ATG dose was 50%, 34%, and 15% (P = .04), respectively. In patients with r-IgG < or = 70 microg/mL (n = 54) the cumulative incidence of grades II-IV aGVHD was 33% compared with only 6% in those with r-IgG >70 microg/mL (n = 18), P = .023. Low serum levels of r-IgG seem to be a strong predictor for aGVHD grades II-IV in patients treated with Thymoglobulin before unrelated donor HSCT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589490     DOI: 10.1016/j.bbmt.2009.04.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Discrepancy in the kinetics of total and active anti-thymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Akiko Yamane; Takehiko Mori; Jun Kato; Yukako Ono; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

Review 2.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

3.  ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.

Authors:  Andrea Bacigalupo
Journal:  Blood Adv       Date:  2017-03-28

4.  ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.

Authors:  Natasha Kekre; Joseph H Antin
Journal:  Blood Adv       Date:  2017-03-28

Review 5.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

6.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Robert J Soiffer; Jennifer Lerademacher; Vincent Ho; Fangyu Kan; Andrew Artz; Richard E Champlin; Steven Devine; Luis Isola; Hillard M Lazarus; David I Marks; David L Porter; Edmund K Waller; Mary M Horowitz; Mary Eapen
Journal:  Blood       Date:  2011-04-04       Impact factor: 22.113

7.  Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.

Authors:  Qaiser Bashir; Mark F Munsell; Sergio Giralt; Leandro de Padua Silva; Manish Sharma; Daniel Couriel; Alexandre Chiattone; Uday Popat; Muzaffar H Qazilbash; Marcelo Fernandez-Vina; Richard E Champlin; Marcos J de Lima
Journal:  Leuk Lymphoma       Date:  2011-12-05

8.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

Authors:  Mark Bosch; Manveer Dhadda; Mette Hoegh-Petersen; Yiping Liu; Laura M Hagel; Peter Podgorny; Alejandra Ugarte-Torres; Faisal M Khan; Joanne Luider; Iwona Auer-Grzesiak; Adnan Mansoor; James A Russell; Andrew Daly; Douglas A Stewart; David Maloney; Michael Boeckh; Jan Storek
Journal:  Cytotherapy       Date:  2012-09-18       Impact factor: 5.414

9.  Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.

Authors:  Galena Salem; Amy S Ruppert; Patrick Elder; Craig C Hofmeister; Don M Benson; Sam Penza; Leslie Andritsos; Rebecca Klisovic; Sumithira Vasu; William Blum; Steven M Devine; Samantha Jaglowski; Yvonne A Efebera
Journal:  Leuk Lymphoma       Date:  2014-11-20

10.  Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation.

Authors:  Lisa V E Oostenbrink; Cornelia M Jol-van der Zijde; Katrine Kielsen; Anja M Jansen-Hoogendijk; Marianne Ifversen; Klaus G Müller; Arjan C Lankester; Astrid G S van Halteren; Robbert G M Bredius; Marco W Schilham; Maarten J D van Tol
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.